The primary objective of Hana’s Phase II study is to assess the efficacy of Marqibo as determined by response rates in patients with uveal melanoma. Secondary objectives are to assess the safety and antitumor activity of Marqibo as determined by response duration, time to progression and overall survival.
The patient population is defined as adults with uveal melanoma and confirmed metastatic disease that is untreated or that has progressed following one prior therapy. Hana expects to enroll up to 30 patients in this clinical trial, which is being conducted at the University of Texas MD Anderson Cancer Center.
Uveal melanoma is a relatively rare cancer of the colored part of the eye and the surrounding areas, called the uvea. Uveal melanoma is the most common primary intraocular malignant tumor in adults and represents 5-6% of all melanoma diagnoses.